AI Article Synopsis

  • The study investigates the effectiveness of two immunoassays (Elecsys® and Kryptor) in measuring sFlt-1 and PlGF levels to diagnose preeclampsia in pregnant women.
  • The analysis includes serum samples from 113 women with preeclampsia and 270 controls, highlighting significant differences in measurements between the two methods.
  • While both tests showed high correlation, the findings suggest that the cut-off values for diagnosing preeclampsia established for one assay may not be applicable to the other, pointing to the need for method-specific thresholds.

Article Abstract

Background For pregnant women with suspected preeclampsia, the soluble fms-like tyrosine-kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio is a biomarker to aid diagnosis. We performed method comparisons between Elecsys® and Kryptor sFlt-1 and PlGF immunoassays and assessed the diagnostic performance for preeclampsia. Methods Serum samples from a case-control study involving 113 pregnant women with preeclampsia/elevated liver enzymes and low platelet count (HELLP) and 270 controls were analyzed. sFlt-1 and PlGF were measured using Roche Elecsys® and BRAHMS Kryptor sFlt-1/PlGF immunoassays. The sFlt-1/PlGF ratios were calculated, and Passing-Bablok regression/Bland-Altman plots were performed. Gestation-specific cut-offs, ≤33 and ≥85/≥110, were assessed. Results Mean (±2 standard deviation [SD]) differences between the Elecsys® and Kryptor values were: sFlt-1, 173.13 pg/mL (6237.66, -5891.40); PlGF, -102.71 pg/mL (186.06, -391.48); and sFlt-1/PlGF, 151.74 (1085.11, -781.63). The Elecsys® and Kryptor immunoassays showed high correlation: Pearson's correlation coefficients were 0.913 (sFlt-1) and 0.945 (PlGF). Slopes were 1.06 (sFlt-1) and 0.79 (PlGF), resulting in ~20% lower values for Kryptor PlGF. Sensitivities and specificities using the sFlt-1/PlGF ≥85 cut-off for early-onset preeclampsia (20 + 0 to 33 + 6 weeks) were 88.1%/100.0% (Elecsys®) and 90.5%/96.2% (Kryptor), respectively, and using the ≥110 cut-off for late-onset preeclampsia (≥34 + 0 weeks) were 51.3%/96.5% (Elecsys®) and 78.9%/90.1% (Kryptor), respectively. Using Elecsys® and Kryptor sFlt-1/PlGF, 0% and 3.8% of women, respectively, were falsely ruled-in for early-onset, and 3.5% and 9.9%, respectively, for late-onset preeclampsia. Conclusions Despite high correlation between the Elecsys® and Kryptor immunoassays, we observed significant differences between sFlt-1/PlGF and PlGF results. Therefore, sFlt-1/PlGF cut-offs validated for Elecsys® immunoassays are not transferable to Kryptor immunoassays.

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2018-1228DOI Listing

Publication Analysis

Top Keywords

elecsys® kryptor
24
kryptor immunoassays
16
sflt-1 plgf
12
elecsys®
10
kryptor
10
plgf
9
pregnant women
8
kryptor sflt-1/plgf
8
high correlation
8
late-onset preeclampsia
8

Similar Publications

Article Synopsis
  • The study assessed the effectiveness of the Vitros® PCT assay in evaluating procalcitonin (PCT) levels for guiding antibiotic therapy and assessing risk in patients with lower respiratory infections or sepsis.
  • Results showed that Vitros PCT closely matched the KRYPTOR PCT assay, with a high correlation and precision, indicating reliable performance for clinical decision-making regarding sepsis.
  • Findings suggested that changes in PCT levels over the first four days could predict 28-day mortality rates in patients with severe sepsis, highlighting the assay's value in clinical risk assessment.
View Article and Find Full Text PDF

Objective: A link between maternal thyroid function and the placental biomarkers, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), has been brought forward. This study aimed to describe their association in early pregnancy.

Design: Retrospective cohort study.

View Article and Find Full Text PDF

Objective: To compare the diagnostic performance of different manufacturers' immunoassays for the soluble fms-like tyrosine kinase-1 (sFlt-1)-to-placental growth factor (PlGF) ratio with that of a point-of-care (PoC) test for glycosylated fibronectin (GlyFn) in women with suspected pre-eclampsia (PE).

Methods: This was a prospective, single-center, double-blinded, non-interventional study of East Asian women with a singleton pregnancy who presented with hypertension with or without clinical features of PE after 20 weeks' gestation between January 2020 and March 2022. Maternal serum samples were collected at the time of presentation, and subsequent management followed the departmental protocol, based on gestational age, severity of hypertension, fetal condition and presence of severe PE features.

View Article and Find Full Text PDF

Insulin-Induced Copeptin Response in Children and Adolescents to Diagnose Arginine Vasopressin Deficiency.

Horm Res Paediatr

September 2024

Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics I, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.

Introduction: The diagnosis of arginine vasopressin deficiency (AVD, formerly central diabetes insipidus) remains a challenge. In recent years, stimulated copeptin has emerged as a promising tool to diagnose AVD.

Methods: In this single centre retrospective study, we identified paediatric patients with suspected pituitary insufficiency who underwent standard insulin tolerance testing (ITT) previously.

View Article and Find Full Text PDF

Oral Levodopa Stimulates Copeptin Secretion in Children and Adolescents with Intact Posterior Pituitary Function.

Endocr Pract

November 2024

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Electronic address:

Article Synopsis
  • Copeptin stimulation tests are useful for diagnosing polyuria-polydipsia syndrome, and this study explores using oral levodopa as a simpler alternative to intravenous or subcutaneous methods.
  • In a cohort of 44 patients under 18, copeptin levels significantly increased when given oral levodopa, showing a notable difference compared to results from insulin tolerance tests.
  • The findings suggest that oral levodopa effectively stimulates copeptin secretion, which could improve diagnostic approaches for growth hormone deficiencies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!